Cornerstone has put together a Scientific and Medical Advisory Board of world-class experts in oncology, cell metabolism, cancer metabolism and the development of cancer therapeutics.
December 12, 2011 Cornerstone Pharmaceuticals’ cancer metabolism inhibitor, CPI-613, showing promise in Phase I trial for acute myeloid leukemia
More View All